# A Study to Assess the Effect of Maintenance Treatment With Rituximab Versus No Treatment in Participants With Progressive B-Cell Chronic Lymphocytic Leukemia (CLL)

Source: https://onco.cc/trials/nct00718549/  
OnCo record `nct00718549` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Cladribine, Cyclophosphamide and Rituximab in Leukaemia, run by Hoffmann-La Roche, completed.

## Summary

A Study to Assess the Effect of Maintenance Treatment With Rituximab Versus No Treatment in Participants With Progressive B-Cell Chronic Lymphocytic Leukemia (CLL) is a phase 3 interventional study registered as NCT00718549 by Hoffmann-La Roche, with 128 participants recorded, started 2009-07-21 and reaching its primary completion in 2015-09-14. Interventions recorded: Cladribine, Cyclophosphamide, Rituximab. Conditions recorded: Lymphocytic Leukemia, Chronic.

Linked to the drug Cladribine because the registry names it among its interventions and Leukaemia among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT00718549
- Phase: 3
- Setting: A Randomized, Open Label Study to Assess the Effect of Maintenance Treatment With Mabthera (Rituximab) Versus No Treatment, After Induction Treatment With Rituximab, Cladribine and Cyclophosphamide (RCC) on Progression-Free Survival in Previously Untreated Patients With Progressive B-Cell Chronic Lymphocytic Leukemia
- Sponsor: Hoffmann-La Roche
- Enrolled: 128

## Sources

- ClinicalTrials.gov NCT00718549: https://clinicaltrials.gov/study/NCT00718549

## Connected records

- cancers: [Leukaemia (all types)](https://onco.cc/cancers/leukaemia/)
- drugs: [Cladribine](https://onco.cc/drugs/cladribine/), [Cyclophosphamide](https://onco.cc/drugs/cyclophosphamide/), [Rituximab](https://onco.cc/drugs/rituximab/)

---
JSON: https://onco.cc/api/v1/entities/nct00718549.json